Trial Profile
Safety and Immunogenicity of a 3-Dose Schedule of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Diphtheria tetanus and pertussis vaccine; Haemophilus vaccines; Hepatitis B vaccine; Influenza B virus vaccine; Japanese encephalitis vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 13-valent CRM197 vaccine conjugate; Poliovirus vaccine; Rotavirus vaccine; Varicella zoster virus vaccine
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms MET33
- Sponsors Sanofi Pasteur
- 29 Mar 2022 Status changed from recruiting to completed.
- 06 Oct 2021 Planned End Date changed from 1 Jan 2022 to 9 Apr 2022.
- 06 Oct 2021 Planned primary completion date changed from 1 Jan 2022 to 9 Apr 2022.